MedTech Earnings in the Age of Ozempic May Not Be That Bad

日本 ニュース ニュース

MedTech Earnings in the Age of Ozempic May Not Be That Bad
日本 最新ニュース,日本 見出し
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 43 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 97%

September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.

The September quarter saw the biggest plunge in medical-device stocks since 2020s lockdowns. Dragging them were fears that new weight-loss drugs will slash demand for devices that treat diabetes, sleep problems, and other weight-related conditions.

Sour sentiment on device stocks has compelled Petrone and most other medtech analysts to reduce their price targets. But feedback from doctors convinces him that September-quarter sales and earnings for most of the companies will be okay. The Mizuho analyst doesn’t cover diabetes-device stocks such as DexCom and Insulet that have suffered some of the steepest selloffs. Businesses that treat sleep apnea also lost favor, and the analyst thinks that investors could be pleasantly surprised by September results from ResMed and Inspire Medical Systems . He rates both shares at Buy.

September-quarter sales volumes were also good for ResMed, Petrone believes. In the long term, weight-loss drugs may cut demand, but he figures ResMed will show sales of $4.6 billion, and earnings per share of $7.04, when it reports on Oct. 26.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

MarketWatch /  🏆 3. in US

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeJohnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.  
続きを読む »

Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeJohnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.  
続きを読む »

New Playground, New Court, New Classroom? Thank Ozempic.New Playground, New Court, New Classroom? Thank Ozempic.Philanthropies with large stakes in weight-loss drugmakers Eli Lilly and Novo Nordisk have surged in value and are now among the biggest in the world
続きを読む »

Eating veggies first can help you lose weight like a 'small form of Ozempic'Eating veggies first can help you lose weight like a 'small form of Ozempic'Your parents were on to something when they told you to eat your veggies first.
続きを読む »

How Do Ozempic, Wegovy & Mounjaro Compare for Weight Loss?How Do Ozempic, Wegovy & Mounjaro Compare for Weight Loss?Your ultimate source for expert nutrition tips and health advice, covering wellness, healthy recipes, cooking hacks, food news, style trends and shopping.
続きを読む »



Render Time: 2025-02-28 09:26:40